中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝纤维化逆转病理PIR分型临床应用的评价

张梦阳 孙亚朦 赵新颜 尤红

引用本文:
Citation:

肝纤维化逆转病理PIR分型临床应用的评价

DOI: 10.3969/j.issn.1001-5256.2019.06.039
基金项目: 

艾滋病和病毒性肝炎等重大传染病防治(2018ZX10302-204,2017ZX10203202-003); 

详细信息
  • 中图分类号: R575.2

Clinical application of PIR classification in the evaluation of liver fibrosis regression

Research funding: 

 

  • 摘要: 肝穿活组织检查方法是评价肝纤维化逆转的"金标准"。北京友谊医院肝病中心于2017年提出了评价慢性乙型肝炎患者抗病毒治疗后肝纤维化逆转的病理新标准:PIR分型,也称为"北京标准"。该分型是继传统分期分级系统及全定量肝纤维化评估方法后,在肝穿病理评估理念上取得的新突破。现重点探讨了PIR分型的应用前景和现有的不足。

     

  • [1]SUN YM, ZHOU JL, WANG L, et al.New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J].Hepatology, 2017, 65 (5) :1438-1450.
    [2]WANLESS IR, NAKASHIMA E, SHERMAN M.Regression of human cirrhosis.Morphologic features and the genesis of incomplete septal cirrhosis[J].Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.
    [3]BEDOSSA P, POYNARD T, French METAVIR Cooperative Study Group.An algorithm for the grading of activity in chronic hepatitis C[J].Hepatology, 1996, 24 (2) :289-293.
    [4]ISHAK KG, BAPTISTA A, BIANCHI L, et al.Histological grading and staging of chronic hepatitis[J].J Hepatol, 1995, 22 (6) :696-699.
    [5]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow-up study[J].Lancet, 2013, 381 (9865) :468-475.
    [6]TSOCHATZIS E, BRUNO S, ISGRO G, et al.Collagen proportionate area is superior to other histological methods for subclassifying cirrhosis and determining prognosis[J].J Hepatol, 2014, 60 (5) :948-954.
    [7]XU S, WANG Y, TAI DCS, et al.qFibrosis:A fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].J Hepatol, 2014, 61 (2) :260-269.
    [8]NAGULA S, JAIN D, GROSZMANN RJ, et al.Histologicalhemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis[J].J Hepatol, 2006, 44 (1) :111-117.
    [9]SETHASINE S, JAIN D, GROSZMANN RJ, et al.Quantitative histological-hemodynamic correlations in cirrhosis[J].Hepatology, 2012, 55 (4) :1146-1153.
    [10]ZIPPRECH A, GARCIA-TSAO G, ROGOWSKI S, et al.Prognostic indicators of survival in patients with compensated and decompensated cirrhosis[J].Liver Int, 2012, 32 (9) :1407-1414.
    [11]RIPOLL C, BANARES R, RINCON D, et al.Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era[J].Hepatology, 2005, 42 (4) :793-801.
    [12]KIM MY, CHO MY, BAIK SK, et al.Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension[J].J Hepatol, 2011, 55 (5) :1004-1009.
    [13]KIM SU, OH HJ, WANLESS IR, et al.The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis[J].J Hepatol, 2012, 57 (3) :556-563
    [14]CHON YE, PARK JY, MYOUNG SM, et al.Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis[J].Am J Gastroenterol, 2017, 112 (6) :882-891.
    [15]LIANG X, XIE Q, TAN D, et al.Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy:A 2-year prospective study[J].J Viral Hepat, 2018, 25 (3) :296-305.
    [16]DONG XQ, ZHAO W, LI J, et al.Declining in liver stiffness can not indicate fibrosis regression in patients with chronic hepatitis B:A 78-week prospective study[J].J Gastroenterol Hepatol, 2019, 34 (4) :755-763..
    [17]KIM WR, BERG T, ASSELAH T, et al.Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J].J Hepatol, 2016, 64 (4) :773-780.
    [18]KONG YY, SUN YM, ZHOU JL, et al.Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir[J].J Viral Hepat, 2019.[Epub ahead of print]
    [19]HE ZY, WANG BQ, YOU H.Clinical application of quantitative assessment of liver fibrosis based on pathology and imaging technology[J].J Clin Hepatol, 2018, 35 (1) :20-23. (in Chinese) 何志颖, 王冰琼, 尤红.基于病理和影像学的肝纤维化量化评估技术的临床应用[J].临床肝胆病杂志, 2018, 35 (1) :20-23.
    [20]WANG B, SUN Y, ZHOU J, et al.Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients[J].Mod Pathol, 2018, 31 (10) :1567-1577.
    [21]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:who and why?[J].Liver Int, 2015, 35 (Suppl 1) :78-81.
    [22]STUECK AE, WANLESS IR.Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis[J].Hepatology, 2015, 61 (5) :1696-1707.
    [23]DEZS K, ROKUSZ A, BUGYIK E, et al.Human liver regeneration in advanced cirrhosis is organized by the portal tree[J].JHepatol, 2017, 66 (4) :778-786.
    [24]XUAN RJ, ZHAO XY, HU DD, et al.Three-dimensional visualization of the microvasculature of bile duct ligation-induced liver fibrosis in rats by X-ray phase-contrast imaging computed tomography[J].Sci Rep, 2015, 5:11500.
    [25]QIN LL, ZHAO XY, JIAN JB, et al.High-resolution 3D visualization of ductular proliferation of bile duct ligation-induced liver fibrosis in rats using X-ray phase contrast computed tomography[J].Sci Rep, 2017, 7 (1) :4215.
    [26]ENOMOTO M, IKURA Y, TAMORI A, et al.Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C[J].United European Gastroenterol J, 2018, 6 (9) :1391-1400.
    [27]D'AMBROSIO R, AGHEMO A, RUMI MG, et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology, 2012, 56 (2) :532-543.
    [28]BEDOSSA P.Pathology of non-alcoholic fatty liver disease[J].Liver Int, 2017, 37 (Suppl 1) :85-89.
  • 加载中
计量
  • 文章访问数:  1195
  • HTML全文浏览量:  65
  • PDF下载量:  337
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-02-03
  • 出版日期:  2019-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回